Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients
Open Access
- 13 December 2005
- Vol. 106 (2) , 466-473
- https://doi.org/10.1002/cncr.21615
Abstract
BACKGROUND Neutropenia is an indicator of poor prognosis in patients with fungal infections. All available clinical trial experience from the caspofungin development program was reviewed to ascertain the efficacy of caspofungin in neutropenic patients with documented invasive aspergillosis (IA) or invasive candidiasis (IC). METHODS The review was limited to neutropenic patients with proven IC or proven/probable IA at caspofungin onset. Data were available from four clinical trials. All patients had an absolute neutrophil count < 500/mm3 at the initiation of caspofungin. In all cases caspofungin was administered as monotherapy at a dose of 50 mg/day, after a 70‐mg loading dose. In all patients efficacy was assessed at the completion of caspofungin therapy. Success included complete and partial responses. RESULTS Sixty‐eight neutropenic patients were identified with documented invasive infection, including 27 with IC and 41 with IA. Most patients had acute or chronic leukemia. A favorable response was noted in 63% (17 of 27 patients) of patients with IC, including a 58% (14 of 24 patients) response as first‐line therapy and a 100% (3 of 3 patients) response as salvage therapy. Success in candidemia was 68% (17 of 25 patients). Outcomes across the different Candida species were similar. Favorable responses were noted in 39% (16 of 41 patients) of patients with IA, including a 42% (5 of 12 patients) response as first‐line therapy and 38% (11 of 29 patients) response as salvage therapy. Success by site of IA was 40% for pulmonary (12 of 30 patients), 43% for sinus (3 of 7 patients), and 25% for skin/disseminated site (1 of 4 patients). CONCLUSIONS A review of the caspofungin database demonstrates that this echinocandin is effective in neutropenic patients with documented cases of IC or IA. Cancer 2006. © 2005 American Cancer Society.Keywords
This publication has 41 references indexed in Scilit:
- Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 2004
- Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use studyJournal of Antimicrobial Chemotherapy, 2004
- Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignanciesCancer, 2003
- A Double‐Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised PatientsClinical Infectious Diseases, 2002
- Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive AspergillosisClinical Infectious Diseases, 2002
- In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates ofEuropean Journal of Clinical Microbiology & Infectious Diseases, 1999
- Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997
- Management of Invasive Candidal Infections: Results of a Prospective, Randomized, Multicenter Study of Fluconazole Versus Amphotericin B and Review of the LiteratureClinical Infectious Diseases, 1996
- Amphotericin B: 30 Years of Clinical ExperienceClinical Infectious Diseases, 1990
- CandidiasisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989